The relation between hypoxia-inducible factor (HIF)=1α and HIF-2α expression with anemia and outcome in surgically treated head and neck cancer

Cancer

Volumn 107, Issue 4, 2006, Pages 757-766

  Winter, Stuart C ^a   Shah, Ketan A ^b   Han, Cheng ^a   Campo, Leticia ^a   Turley, Helen ^a   Leek, Russell ^a   Corbridge, Rogan J ^c   Cox, Graham J ^c   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

Anemia; Dead and neck squamous cell carcinoma; Hypoxia; Hypoxia inducible factor; Surgery

Indexed keywords

CARBONATE DEHYDRATASE IX; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; TUMOR MARKER;

ANEMIA; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OXYGEN TRANSPORT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANOXIA; ANTIGENS, NEOPLASM; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HEMOGLOBINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33747176556     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21983     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
2. Baatenburg de Jong RJ, Hermans J, Molenaar J, Briaire JJ, le Cessie S. Prediction of survival in patients with head and neck cancer. Head Neck. 2001;23:718-724.
3. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994;44:7-26.
4. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952.
5. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
6. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38-47.
7. Robertson N, Potter C, Harris AL. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004;64:6160-6165.
8. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157:411-421.
9. Sowter HM, Raval R, Moore J, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1 alpha versus Hif-2 alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 2003;63:6130-6134.
10. Warnecke C, Zaborowska Z, Kurreck J, et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2 alpha target gene in Hep3B and Kelly cells. FASEB J. 2004;18:1462-1464.
11. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7:492-508.
12. Lutterbach J, Guttenberger R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys. 2000;48:1345-1350.
13. Kelleher DK, Matthiensen U, Thews O, Vaupel P. Tumor oxygenation in anemic rats: effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol. 1995;34:379-384.
14. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol. 2001;28(2 Suppl 8):29-35.
15. Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer. 2002;38:240-257.
16. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803-1804.
17. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:67-71.
18. Dische S. Radiotherapy and anaemia-the clinical experience. Radiother Oncol. 1991;20(Suppl 1):35-40.
19. Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1 alpha and 2 alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002;8:2595-2604.
20. Koukourakis MI,1 Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53:1192-1202.
21. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075-7083.
22. Beasley NJ, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002;62:2493-2497.
23. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res. 2001;7:3399-3403.
24. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Rss. 2001;61:2911-2916.
25. Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157:411-421.
26. Jourdan F, Sebbagh N, Comperat E, et al. Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch. 2003;443:115-121.
27. Van den Eynden GG, Van der Auwera I, Van Laere S, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat. 2004;85:13-22.
28. Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001;61:5262-5267.
29. Hoogsteen IJ, Marres HA, Wijffels KI, et al. Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res. 2005;11:97-106.
30. Kurokawa T, Miyamoto M, Kato K, et al. Overexpression of hypoxia-inducible-factor 1 alpha (HIF-1 alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer. 2003;89:1042-1047.
31. Turner KJ, Crew JP, Wykoff CC, et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial versus invasive bladder cancer. Br J Cancer. 2002;86:1276-1282.
32. White JR, Harris RK, Lee SR, et al. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics. 2004;83:1-8.
33. Covello KL, Simon MC, Keith B. Targeted replacement of hypoxia-inducible factor-1 alpha by a hypoxia-inducible factor-2 alpha knock-in allele promotes tumor growth. Cancer Res. 2005;65:2277-2286.
34. Burri P, Djonov V, Aebersold DM, et al. Significant correlation of hypoxia-inducible factor-1 alpha with treatment outcome in cervical cancer treated with radical radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:494-501.
35. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85:881-890.
36. Simon R, Mirlacher M, Sauter G. Tissue microarrays. Methods Mol Med. 2004;97:377-389.
37. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949.
38. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol. 2002;26:312-319.
39. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249-2256.
40. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
41. Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist. 2000;5(Suppl 2):13-18.
42. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2005;61:1087-1095.
43. Koukourakis MI, Giatromanolaki A, Liberis V, Sivridis E. Hypoxia inducible factor 1 alpha and 2 alpha expression is independent of anemia in patients with stage I endometrial cancer. Anticancer Res. 2002;22:4137-4140.